Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.

Wilex is a biopharmaceutical company focused on oncology and antibodies. The parent company WILEX AG no longer pursues clinical development activities in Munich, instead acting exclusively as a holding company. Operation concentrate on the research and development activities of the subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma workes with the toxin Amanitin and an ADC technology with the goal of coupling this highly effective agent with various antibodies to make it usable for treating cancer. This innovative technology platform is progressively being developed for therapeutic antibody drug conjugates for use in proprietary projects and partnerships.